Scinai Immunotherapeutics Ltd.’s Post

Dr Ashley O'Toole and Dr Melinda Gooderham in Vienna, Austria 🇦🇹 with a group of Canadian delegates to discuss atopic dermatitis, prurigo nodularis and Type 2 inflammation with global colleagues. 👍 This was an excellent opportunity for them to brush up on their presentation skills and exchange insights and their clinical trial experience with dupilumab with international experts in the field. #dermatology #globalcollaboration #Type2inflammation #atopicdermatitis #prurigonodularis

We’re headed to New York this week to present at the MedInvest Biotech & Pharma Investor Conference. CEO Neal Koller will provide an overview of our successful Phase 2a clinical trials in #atopicdermatitis, our work in epidermolysis bullosa, and what’s in store for the year ahead. #venturecapital #clinicaltrials #dermatology #epidermolysisbullosa

The emerging landscape of targeted therapies, particularly biologics and small molecule agents, offers new hope by providing more effective and tailored treatment options. However, the integration of personalized treatment strategies, and patient-centered care remains crucial for optimizing outcomes and enhancing the quality of life for psoriasis patients. This podcast will discuss these key issues and explore the potential of innovative therapies in improving patient outcomes. Follow the link in our bio for FREE AMA, ABS, ANCC or ACPE credit! #psoriasis #dermatology #practicepointcme #freecme

💡Psoriasis Treatment is Evolving! 💡 Spherix Global Insights highlights the excitement around pipeline agents like Johnson & Johnson’s oral IL-23 asset, JNJ-2113, which reflects high expectations for it to capture significant market share, potentially outpacing other oral candidates and shifting the timelines for initiating biologic treatments. Competing with JNJ-2113 in the pipeline are several promising TYK2 inhibitors, including ESK-001 from Alumis, zasocitinib (TAK-279) from Takeda, and BMS-986322 from Bristol Myers Squibb. With patient preference shifting towards oral options, these innovative treatments could reshape the market and improve care. Read more: https://lnkd.in/e4JfAKMy #Psoriasis #Dermatology #EmergingTherapies #MarketResearch

In dermatology news, a new post-hoc analysis from April Armstrong, MD MPH, and colleagues showed treatment with ixekizumab (Taltz; Eli Lilly and Company) resulted in a greater rate of acceptable responses among patients with psoriasis than other biologics. Want to learn more? View our summary of the findings here: https://lnkd.in/e9d2DKF7 #Dermatology #Psoriasis

🚨 New data at #FallClinical: Lebrikizumab-lbkz (Ebyglyss) treatment of moderate-to-severe #AtopicDermatitis led to improvements in patients’ skin (including hands and face) and itch among those who were previously treated with dupilumab. These findings were announced by Elil Lilly & Company and authored by such investigators as Linda Stein Gold, MD, of Henry Ford Health. To learn more, check out our summary here: https://lnkd.in/g6dnUyCF #dermatology #lebrikizumab #eczema

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝗖𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗦𝗺𝗮𝗹𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 𝗮𝗻𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease that significantly affects #healthcare systems #globally, with approximate prevalence of 40,805,386 cases. Minapharm, with extensive expertise in #dermatology, is at the forefront of advancing #Psoriasis treatments by offering a range of #innovative products through its dedicated Psoriasis portfolio composed of both small molecules as well as monoclonal antibodies. Learn more: https://lnkd.in/da6KW2K5 #Minapharm #Innovationmadeaffordable #egypt #africa #PsoriasisAwarenessMonth

New article in Drugs in Context Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature Anna Paola Lugli, Giacomo Caldarola, Gianmarco Falco, Costanza Montedoro, Camilla Mulas, Clara De Simone Article describing two cases of new-onset bullous pemphigoid in patients treated with anti-IL-17 drugs for psoriasis. #drugsincontext #dermatology #mabs #IL17 #treatment #pharmacology https://lnkd.in/dqenggh3

New in Drugs in Context New and emerging oral therapies for psoriasis Orhan Yilmaz, João Pedro Pinto, Tiago Torres Narrative review synthesizing the emerging oral therapeutic agents for psoriasis, such as PDE4 and TYK2 inhibitors, focusing on their mechanisms of action, stages of development and clinical trial results. #drugsincontext #dermatology #psoriasis #therapies #emergingtreatments #pharmacology https://lnkd.in/dSxC227K

During the National Congress of Dermatology and Venereology, we had the opportunity to present four studies: On Psoriasis: - Efficacy and Safety of Oral Roflumilast in the Treatment of Psoriasis: A Prospective Study - Efficacy and Safety of Spesolimab in the Treatment of Flares of Generalized Pustular Psoriasis - Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis On Atopic Dermatitis: - Drug Survival of Dupilumab, Tralokinumab and Upadacitinib in Patients with Atopic Dermatitis – an International, Real-World Comparative Study Many thanks to Ana Maria Lé, Martim Luz, and José Miguel Alvarenga for their collaboration in presenting these studies. #SPDV #dermatology #psoriasis #atopicdermatitis